1), the study population was divided as follows: the GLP-1RA cohort consisted of patients prescribed initial GLP-1RAs between April 2013 and April 2019 who were never prescribed SGLT2 inhibitors before the initial GLP-1RAs prescription, and the SGLT2 cohort consisted of patients prescribed initial SGLT2 inhibitors between April 2013 and April 2019 who were never prescribed GLP-1RAs before the initial SGLT2 prescription
The most notable practical difference in their profiles is the drug interaction with oral contraceptives, which requires specific counseling and management for Tirzepatide but not for semaglutide
Ultimately, the choice between these two compounds depends on the specific goals of the research
doi: 10.1081/FRI-120003416 137 AllwoodJGWakelingLTBeanDC
Glutathione in multiple sclerosis: more than just an antioxidant
With this authorization, RJVA-001 becomes the first AAV gene therapy candidate to enter clinical development for type 2 diabetes, said Rajagopalan